Jefferies & Company Raises Price Target For Gen-Probe Incorporated (GPRO)

Analyst Bruce Cranna at Jefferies & Company Inc. has released an update on Gen-Probe Incorporated (NASDAQ: GPRO). On Thursday, the company reported its first-quarter results.

Gen-Probe reported first-quarter non-GAAP EPS of $0.48, beating Jefferies and consensus estimate by $0.04. First-quarter revenue stood at $135.4 million, beating consensus estimate by $2.5 million. The earnings upside was due to better sales from Clinical Diagnostics and higher other income.

Jefferies & Company has raised the price target for Gen-Probe from $54 to $56. The brokerage firm has maintained its Buy rating for the company.